Table 3.

Efficacy of qHPV vaccine.

Variable	HIV-MSM Vaccine (n = 65)	HIV-MSM Placebo (n = 63)	*p
HSIL
12 m–48 m, n (%)	9 (14.1)	8 (13.1)	0.87
12 m, n (%)	7/63 (11.1)	7/61 (11.4)	1
24 m, n (%)	0 (0)	1/50 (2)	0.47
36 m, n (%)	1/53 (1.9)	0 (0)	1
48 m, n (%)	1/50 (2)	0 (0)	1
EAGL/Condyloma
12 m–48 m, n (%)	7 (11.1)	4 (6.8)	0.40.6
12 m, n (%)	3 (4.6)	1 (1.7)	0.7
24 m, n (%)	2/54 (3.7)	3/51 (5.9)	0.5
36 m, n (%)	2/52 (3.8)	0 (0)	1
48 m, n (%)	0 (0)	0 (0)
Acquisition HPV Genotypes 12 m	n = 53	n = 47
HPV 6, n (%)	4 (7.5)	11 (23.4)	0.047
HPV 11, n (%)	4 (7.5)	3 (6.3)	1
HPV 16, n (%)	12 (25.5)	10 (24.4)	1
HPV 18, n (%)	9 (15.8)	6 (11.8)	0.55
Acquisition HPV Genotypes 24 m	n = 48	n = 43
HPV 6, n (%)	4 (8.3)	2 (4.6)	0.69
HPV 11, n (%)	6 (13)	1 (2.3)	0.11
HPV 16, n (%)	3 (9.4)	4 (9.3)	1
HPV 18, n (%)	3 (6.1)	1 (2.3)	0.62
Acquisition HPV Genotypes 36 m	n = 37	n = 34
HPV 6, n (%)	1 (2.7)	3 (8.8)	0.34
HPV 11, n (%)	2 (5.4)	0 (0)	0.49
HPV 16, n (%)	4 (10.8)	1 (2.9)	0.36
HPV 18, n (%)	2 (5.4)	0 (0)	0.49
Acquisition HPV Genotypes 48 m	n = 30	n = 27
HPV 6, n (%)	3 (10)	1 (3.7)	0.62
HPV 11, n (%)	0 (0)	0 (0)	1
HPV 16, n (%)	2 (6.7)	1 (3.7)	1
HPV 18, n (%)	2 (6.7)	0 (0)	0.49

*p < 0.005.